cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Athira Pharma Inc
19 own
10 watching
Current Price
$0.53
$-0.04
(-6.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
20.3M
52-Week High
52-Week High
4.29800
52-Week Low
52-Week Low
0.41200000
Average Volume
Average Volume
0.56M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization20.3M
icon52-Week High4.29800
icon52-Week Low0.41200000
iconAverage Volume0.56M
iconDividend Yield--
iconP/E Ratio--
What does the Athira Pharma Inc do?
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
Read More
How much money does Athira Pharma Inc make?
News & Events about Athira Pharma Inc.
Globe Newswire
1 year ago
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET systemBOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
Zolmax
1 year ago
Athira Pharma, Inc. (NASDAQ:ATHA Get Rating) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,050,000 shares, a growth of 5.7% from the February 13th total of 1,940,000 shares. Based on an average daily volume ...
Globe Newswire
1 year ago
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseasesBOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc.(NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on ...
Globe Newswire
2years ago
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimers disease is progressing with targeted enrollment ...
Globe Newswire
2years ago
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal modelsBOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...
Frequently Asked Questions
Frequently Asked Questions
What is Athira Pharma Inc share price today?
plus_minus_icon
Can Indians buy Athira Pharma Inc shares?
plus_minus_icon
How can I buy Athira Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Athira Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Athira Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Athira Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Athira Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Athira Pharma Inc?
plus_minus_icon
What percentage is Athira Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Athira Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.53
$-0.04
(-6.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$2.56
$-0.19 (-6.91 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$1.39
$-0.07 (-4.79 %)
Clene Inc
Clene Inc
$4.99
$-0.20 (-3.86 %)
BioAtla Inc
BioAtla Inc
$0.49
$-0.04 (-7.11 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
$2.56
$-0.19 (-6.91 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$1.39
$-0.07 (-4.79 %)
Clene Inc
Clene Inc
$4.99
$-0.20 (-3.86 %)
BioAtla Inc
BioAtla Inc
$0.49
$-0.04 (-7.11 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00